<DOC>
	<DOCNO>NCT02784002</DOCNO>
	<brief_summary>The purpose research study evaluate safety effectiveness Ridinilazole ( SMT19969 ) treat C. difficile Infection ( CDI ) .</brief_summary>
	<brief_title>A Study Ridinilazole ( SMT19969 ) Compared With Fidaxomicin Treatment Clostridium Difficile Infection ( CDI )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<criteria>Informed Consent Clinical diagnosis CDI plus laboratory diagnostic test No 30 hour antimicrobial treatment current CDI episode Female subject childbearing potential must use adequate contraception Lifethreatening fulminant CDI Subjects 2 episode CDI previous year Females pregnant breastfeed History inflammatory bowel disease Coadministration potent Pglycoprotein inhibitor Participation Clinical research study within one month screen Subjects Investigator feel inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>